WO2004063336A3 - Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis - Google Patents

Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis Download PDF

Info

Publication number
WO2004063336A3
WO2004063336A3 PCT/US2004/000293 US2004000293W WO2004063336A3 WO 2004063336 A3 WO2004063336 A3 WO 2004063336A3 US 2004000293 W US2004000293 W US 2004000293W WO 2004063336 A3 WO2004063336 A3 WO 2004063336A3
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
treatment
deazapurines
bone metastasis
reperfusion injuries
Prior art date
Application number
PCT/US2004/000293
Other languages
French (fr)
Other versions
WO2004063336A2 (en
Inventor
Jane Daun
Scott Field
Seiichi Kobayashi
Original Assignee
Eisai Co Ltd
Jane Daun
Scott Field
Seiichi Kobayashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/000366 external-priority patent/WO2003057696A1/en
Application filed by Eisai Co Ltd, Jane Daun, Scott Field, Seiichi Kobayashi filed Critical Eisai Co Ltd
Publication of WO2004063336A2 publication Critical patent/WO2004063336A2/en
Publication of WO2004063336A3 publication Critical patent/WO2004063336A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The present invention provides methods of using compounds having formula (I) : wherein R1, R2, R3 and n are as described generally and in classes and subclasses herein, in the treatment of reperfusion injuries, osteoporosis and/or bone metastasis.
PCT/US2004/000293 2003-01-07 2004-01-07 Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis WO2004063336A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/000366 WO2003057696A1 (en) 2002-01-07 2003-01-07 Deazapurines and uses thereof
USPCT/US03/00366 2003-01-07

Publications (2)

Publication Number Publication Date
WO2004063336A2 WO2004063336A2 (en) 2004-07-29
WO2004063336A3 true WO2004063336A3 (en) 2004-08-26

Family

ID=32710267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000293 WO2004063336A2 (en) 2003-01-07 2004-01-07 Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis

Country Status (2)

Country Link
TW (1) TWI322807B (en)
WO (1) WO2004063336A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111495B (en) 2005-02-02 2011-06-15 卫材R&D管理有限公司 Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434405A1 (en) * 1989-12-21 1991-06-26 American Home Products Corporation Imidazo[4,5-c]pyridines as antiosteoporotic agents
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434405A1 (en) * 1989-12-21 1991-06-26 American Home Products Corporation Imidazo[4,5-c]pyridines as antiosteoporotic agents
WO2001030778A1 (en) * 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABRAHAMSEN B ET AL: "CYTOKINES AND BONE LOSS IN A 5-YEAR LONGITUDINAL STUDY- HORMONE REPLACEMENT THERAPY SUPPRESSES SERUM SOLUBLE INTERLEUKIN-6 RECEPTOR AND INCREASES INTERLEUKIN-1-RECEPTOR ANTAGONIST: THE DANISH OSTEOPOROSIS PREVENTION STUDY", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 15, no. 8, August 2000 (2000-08-01), pages 1545 - 1554, XP001012963, ISSN: 0884-0431 *
CAIN B S ET AL: "p38 MAPK Inhibition Decreases TNF-alpha Production and Enhances Postischemic Human Myocardial Function", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 83, no. 1, 1 May 1999 (1999-05-01), pages 7 - 12, XP002213908, ISSN: 0022-4804 *
DANIELLE G. SOUZA ET AL.: "Effects of inhibition of PDE4 and TNF-a on local and remote injuries following ischaemia and reperfusion injury", BRITISH JOURNAL OF OHARMACOLOGY, vol. 134, no. 5, November 2001 (2001-11-01), LONDON, pages 985 - 994, XP002287701 *
KOYANO T ET AL: "EFFECTS OF FR167653 ON ISCHEMIA-REPERFUSION INJURY: EVALUATION THROUGH PRESERVATION AND TRANSPLANTATION IN CANINE HEARTS", JOURNAL OF HEART AND LUNG TRANSPLANTATION, MOSBY-YEAR BOOK, INC., ST LOUIS, MO, US, vol. 17, no. 12, December 1998 (1998-12-01), pages 1247 - 1254, XP001105182, ISSN: 1053-2498 *
YOSHIAKI AZUMA ET AL.: "Tumor Necrosis Factor-a Induces Differentiaion of and Bone Resorption by Osteoclasts", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 275, no. 7, 18 February 2000 (2000-02-18), USAMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., pages 4858 - 4864, XP002287700 *

Also Published As

Publication number Publication date
TW200412345A (en) 2004-07-16
TWI322807B (en) 2010-04-01
WO2004063336A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
WO2004074244A3 (en) Pyrimidine compounds
RS20050810A (en) 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
WO2007017289A3 (en) Acyltryptophanols for fertility control
HK1068626A1 (en) Chemical compounds
CY1111050T1 (en) PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES
IL180722A0 (en) Thienopyrimidine derivatives and pharmaceutical compositions containing the same
UA87991C2 (en) Substituted indole-o-glucosides
EP1432714A4 (en) Chemical compounds
WO2007106192A3 (en) Inhibitors of iap
MXPA05002440A (en) Compositions and kits for the removal of irritating compounds from bodily surfaces.
GB0307834D0 (en) Composition
TW200604197A (en) New compounds
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
WO2005030794A3 (en) Hemiasterlin derivatives and uses thereof
MXPA06003345A (en) Aminopyridine-derivatives as inductible no-synthase inhibitors.
WO2004087652A3 (en) Imidazotriazine compounds
MXPA06000372A (en) Silicon compounds and their use.
WO2004063336A3 (en) Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
TW200503672A (en) 2-aminobenzoyl derivatives
MX2007006094A (en) 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase